AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom, with a presence in more than 100 countries. The company is engaged in the discovery, development, manufacturing and commercialization of prescription medicines in key therapeutic areas, including oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology.
The modern AstraZeneca was formed in 1999 through the merger of Sweden’s Astra AB and the British pharmaceutical firm Zeneca Group. Since then, the company has invested heavily in research and development, operating multiple R&D centers across Europe, North America and the Asia-Pacific region. Its research pipeline spans small molecules, biologics and antibody–drug conjugates, with an emphasis on precision medicine and the application of novel technologies such as messenger RNA and cell therapy.
Among AstraZeneca’s well-known products are Tagrisso (osimertinib) for non–small cell lung cancer, Imfinzi (durvalumab) for various solid tumors, Farxiga (dapagliflozin) for cardiorenal and metabolic disorders, and Symbicort (budesonide/formoterol) for asthma and chronic obstructive pulmonary disease. The company’s portfolio is supplemented by strategic acquisitions and collaborations, including its 2021 acquisition of rare disease specialist Alexion Pharmaceuticals, which expanded its presence in immunology and complement biology.
Under the leadership of Chief Executive Officer Pascal Soriot, AstraZeneca emphasizes sustainable growth and patient access through partnerships with governments, non-profit organizations and academic institutions. The company continues to leverage its global footprint to address unmet medical needs and advance innovations that improve health outcomes worldwide.
AI Generated. May Contain Errors.
